NASDAQ:SIEN Sientra Stock Forecast, Price & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Sientra Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $3.58 +0.02 (+0.56 %) (As of 09/22/2020 12:00 AM ET) Add Compare Share Today's Range$3.51Now: $3.58▼$3.6750-Day Range$3.27MA: $3.74▼$4.2452-Week Range$1.00Now: $3.58▼$9.71Volume296,169 shsAverage Volume1.21 million shsMarket Capitalization$180.12 millionP/E RatioN/ADividend YieldN/ABeta1.52 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Sientra, Inc., a medical aesthetics company, develops and sells medical aesthetics products to plastic surgeons in the United States. It operates through two segments, Breast Products and miraDry. The company offers silicone gel breast implants for use in breast augmentation and breast reconstruction procedures; breast tissue expanders; and scar management products under the Sientra, AlloX2, OPUS, Dermaspan, Softspan, and BIOCORNEUM brand names. It also provides body contouring products; facial and nasal implants; saline filled breast implant sizers; and miraDry System, a non-surgical device for the permanent reduction of underarm sweat, odor, and hair of all colors. The company was formerly known as Juliet Medical, Inc. and changed its name to Sientra, Inc. in April 2007. Sientra, Inc. was incorporated in 2003 and is headquartered in Santa Barbara, California.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingSientra has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $6.80, Sientra has a forecasted upside of 89.9% from its current price of $3.58.Amount of Analyst CoverageSientra has only been the subject of 3 research reports in the past 90 days. Previous Next 2.3 Community Rank Outperform VotesSientra has received 257 “outperform” votes. (Add your “outperform” vote.)Underperform VotesSientra has received 312 “underperform” votes. (Add your “underperform” vote.)Community SentimentSientra has received 54.83% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Sientra and other stocks. Vote “Outperform” if you believe SIEN will outperform the S&P 500 over the long term. Vote “Underperform” if you believe SIEN will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldSientra does not currently pay a dividend.Dividend GrowthSientra does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Sientra insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.80% of the stock of Sientra is held by insiders.Percentage Held by Institutions76.86% of the stock of Sientra is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Sientra are expected to grow in the coming year, from ($1.60) to ($1.21) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Sientra is -1.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Sientra is -1.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSientra has a P/B Ratio of 2.17. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.5Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.49 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Surgical appliances & supplies Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:SIEN Previous Symbol CUSIPN/A CIK1551693 Webwww.sientra.com Phone805-562-3500Debt Debt-to-Equity Ratio2.87 Current Ratio2.85 Quick Ratio1.95Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$83.70 million Price / Sales2.15 Cash FlowN/A Price / Cash FlowN/A Book Value$1.65 per share Price / Book2.17Profitability EPS (Most Recent Fiscal Year)($2.29) Net Income$-106,820,000.00 Net Margins-140.76% Return on Equity-130.33% Return on Assets-39.95%Miscellaneous Employees339 Outstanding Shares50,312,000Market Cap$180.12 million Next Earnings Date11/5/2020 (Estimated) OptionableOptionable $3.58 +0.02 (+0.56 %) (As of 09/22/2020 12:00 AM ET) 30 days | 90 days | 365 days | Advanced Chart Receive SIEN News and Ratings via Email Sign-up to receive the latest news and ratings for SIEN and its competitors with MarketBeat's FREE daily newsletter. Sientra (NASDAQ:SIEN) Frequently Asked Questions How has Sientra's stock been impacted by Coronavirus? Sientra's stock was trading at $2.44 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, SIEN shares have increased by 46.7% and is now trading at $3.58. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of Sientra? 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sientra in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Sientra. When is Sientra's next earnings date? Sientra is scheduled to release its next quarterly earnings announcement on Thursday, November 5th 2020. View our earnings forecast for Sientra. How were Sientra's earnings last quarter? Sientra Inc (NASDAQ:SIEN) posted its earnings results on Monday, August, 10th. The medical instruments supplier reported ($0.68) EPS for the quarter, missing the Zacks' consensus estimate of ($0.45) by $0.23. The medical instruments supplier earned $12.45 million during the quarter, compared to analyst estimates of $8.87 million. Sientra had a negative net margin of 140.76% and a negative return on equity of 130.33%. View Sientra's earnings history. What price target have analysts set for SIEN? 6 Wall Street analysts have issued 1 year target prices for Sientra's stock. Their forecasts range from $5.00 to $9.00. On average, they anticipate Sientra's stock price to reach $6.80 in the next twelve months. This suggests a possible upside of 89.9% from the stock's current price. View analysts' price targets for Sientra. Are investors shorting Sientra? Sientra saw a decrease in short interest in August. As of August 31st, there was short interest totaling 3,120,000 shares, a decrease of 17.7% from the August 15th total of 3,790,000 shares. Based on an average trading volume of 1,000,000 shares, the short-interest ratio is currently 3.1 days. Approximately 7.2% of the company's stock are sold short. View Sientra's Short Interest. Who are some of Sientra's key competitors? Some companies that are related to Sientra include Inogen (INGN), Establishment Labs (ESTA), Invacare (IVC), RTI Surgical (RTIX), Alpha Pro Tech (APT), Lakeland Industries (LAKE), Milestone Scientific (MLSS), ConforMIS (CFMS), COLLPLANT HOLDI/S (CLGN), Histogenics (HSGX), Allied Healthcare Products (AHPI), Rewalk Robotics (RWLK), Myomo (MYO), Advanced Biomedical Technologies (ABMT) and Precision Therapeutics (POAI). View all competitors. What other stocks do shareholders of Sientra own? Based on aggregate information from My MarketBeat watchlists, some companies that other Sientra investors own include Micron Technology (MU), Matinas BioPharma (MTNB), Rigel Pharmaceuticals (RIGL), Sorrento Therapeutics (SRNE), Novavax (NVAX), Inovio Pharmaceuticals (INO), Intel (INTC), Miragen Therapeutics (MGEN), ADMA Biologics (ADMA) and Corbus Pharmaceuticals (CRBP). Who are Sientra's key executives? Sientra's management team includes the following people: Mr. Jeffrey M. Nugent, Chairman & CEO (Age 73, Pay $1.92M)Mr. Paul Sean Little, CFO, Sr. VP & Treasurer (Age 55, Pay $513.65k)Mr. Charles Huiner, Consultant (Age 49, Pay $558.46k)Mr. Keith J. Sullivan, Director & Advisor to MiraDry Bus. (Age 62, Pay $40k)Ms. Deborah Bettencourt, VP of HR & Corp. Admin. What is Sientra's stock symbol? Sientra trades on the NASDAQ under the ticker symbol "SIEN." Who are Sientra's major shareholders? Sientra's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Deerfield Management Company L.P. Series C (8.27%), UBS Group AG (4.82%), Mutual of America Capital Management LLC (2.62%), Goldman Sachs Group Inc. (2.49%), Assenagon Asset Management S.A. (1.00%) and HighTower Advisors LLC (0.71%). Company insiders that own Sientra stock include Jeffrey M Nugent, Keith J Sullivan, Paul Sean Little and Timothy Haines. View institutional ownership trends for Sientra. Which major investors are selling Sientra stock? SIEN stock was sold by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., Nuveen Asset Management LLC, Deerfield Management Company L.P. Series C, Two Sigma Advisers LP, AQR Capital Management LLC, UBS Group AG, HighTower Advisors LLC, and SG Americas Securities LLC. View insider buying and selling activity for Sientra. Which major investors are buying Sientra stock? SIEN stock was purchased by a variety of institutional investors in the last quarter, including Mutual of America Capital Management LLC, Assenagon Asset Management S.A., Bridgeway Capital Management Inc., Baird Financial Group Inc., Schonfeld Strategic Advisors LLC, California Public Employees Retirement System, Jane Street Group LLC, and State of Wisconsin Investment Board. Company insiders that have bought Sientra stock in the last two years include Keith J Sullivan, and Paul Sean Little. View insider buying and selling activity for Sientra. How do I buy shares of Sientra? Shares of SIEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Sientra's stock price today? One share of SIEN stock can currently be purchased for approximately $3.58. How big of a company is Sientra? Sientra has a market capitalization of $180.12 million and generates $83.70 million in revenue each year. The medical instruments supplier earns $-106,820,000.00 in net income (profit) each year or ($2.29) on an earnings per share basis. Sientra employs 339 workers across the globe. What is Sientra's official website? The official website for Sientra is www.sientra.com. How can I contact Sientra? Sientra's mailing address is 420 SOUTH FAIRVIEW AVENUE SUITE 200, SANTA BARBARA CA, 93117. The medical instruments supplier can be reached via phone at 805-562-3500 or via email at [email protected] This page was last updated on 9/23/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
